Summary
Large-volume subcutaneous drug delivery in the 2.0–5.0 mL range introduces new considerations for injection time, usability, primary container selection, and manufacturing readiness. In this interview, SHL Medical’s Vince Masciopinto discusses how cartridge-based autoinjector design and Needle Isolation Technology (NIT) can help address these challenges. He explains how fluid-path optimization can improve injection performance without changing the primary container, why compact device design matters for users and supply-chain efficiency, and how early planning across primary packaging, fill-finish, and final assembly can support large-volume combination product development.
Key takeaways
- Evolution of the Maggie platform into Magnitude
- Targeted usability improvements through a redesigned twist-off cap
- Split-cannula NIT configuration providing ~50% improvement in injection time with a 27G patient-end needle
- Fluid-path optimization independent of the primary container and ongoing stability testing
- Compact footprint comparable with standard 2.25 mL autoinjectors while supporting more than twice the delivery volume
- Alliance Network support across primary packaging, fill-finish, final assembly, labeling, and packaging
Document details
- Format: Interview / Article
- Authors/Spokespeople:
Vince Masciopinto, Customer Solutions Director
- Page count: 5 pages
- Estimated read time: ~10 minutes
